Due to the dual meaning of markers of T-cell senescence on CD4+ T cells, i.e., regulation vs. the previous activation, it is difficult to discern whether a high level of CD4+ T-cell senescence in some patients with MS reflects better T-cell regulation in these patients or a higher antigen-specific T-cell activation. This evidence concerns the gene CD4 and myeloid sarcoma.